- Home
- AMTB vs REPL Comparison
AMTB vs REPL Comparison
Compare AMTB & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- REPL
- Stock Information
- Founded
- AMTB 1979
- REPL 2015
- Country
- AMTB United States
- REPL United States
- Employees
- AMTB N/A
- REPL N/A
- Industry
- AMTB Major Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- REPL Health Care
- Exchange
- AMTB Nasdaq
- REPL Nasdaq
- Market Cap
- AMTB 726.3M
- REPL 721.7M
- IPO Year
- AMTB N/A
- REPL 2018
- Fundamental
- Price
- AMTB $19.04
- REPL $10.03
- Analyst Decision
- AMTB Buy
- REPL Buy
- Analyst Count
- AMTB 4
- REPL 9
- Target Price
- AMTB $21.75
- REPL $12.00
- AVG Volume (30 Days)
- AMTB 348.2K
- REPL 2.3M
- Earning Date
- AMTB 10-28-2025
- REPL 11-06-2025
- Dividend Yield
- AMTB 1.90%
- REPL N/A
- EPS Growth
- AMTB N/A
- REPL N/A
- EPS
- AMTB 1.59
- REPL N/A
- Revenue
- AMTB $388,504,000.00
- REPL N/A
- Revenue This Year
- AMTB $61.98
- REPL N/A
- Revenue Next Year
- AMTB $4.00
- REPL N/A
- P/E Ratio
- AMTB $11.94
- REPL N/A
- Revenue Growth
- AMTB 51.98
- REPL N/A
- 52 Week Low
- AMTB $15.62
- REPL $2.68
- 52 Week High
- AMTB $26.24
- REPL $14.80
- Technical
- Relative Strength Index (RSI)
- AMTB 63.49
- REPL 70.49
- Support Level
- AMTB $16.81
- REPL $8.50
- Resistance Level
- AMTB $17.74
- REPL $9.63
- Average True Range (ATR)
- AMTB 0.49
- REPL 0.61
- MACD
- AMTB 0.26
- REPL -0.04
- Stochastic Oscillator
- AMTB 98.94
- REPL 95.59
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.